Cibc Bancorp USA Adds $312M in DexCom, Inc. ($DXCM)
Key Points
- Cibc Bancorp USA changed its DexCom, Inc. ($DXCM) stake by 6060.0% last quarter, boosting to 4,217,134 shares worth $317.34 million.
- Wall Street's consensus rating on $DXCM is Strong Buy and an average price target of $84.67.
- $DXCM last traded around $75.25.
Cibc Bancorp USA increased its position in DexCom, Inc. ($DXCM) by 6060.0% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,217,134 shares of DexCom, Inc. after buying 4,148,674 shares during the quarter. Cibc Bancorp USA's holdings in DexCom, Inc. were worth $317.34 million as of its most recent filing.
DexCom, Inc. ($DXCM) Stock
DexCom, Inc. Earnings
Analysts Set New Price Targets
About DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.